StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)

Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –

Zevra Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Zevra Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 95.5%. For fiscal 2025 it was 84.5%, against 68.6% the year before. The highest annual figure on record is 97.8% in fiscal 2022.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202584.5%+15.9
FY2024Dec 31, 202468.6%−23.5
FY2023Dec 31, 202392.1%−5.7
FY2022Dec 31, 202297.8%+5.0
FY2021Dec 31, 202192.8%+70.7
FY2019Dec 31, 201922.1%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202696.2%+44.0
Q1 FY2026Mar 31, 202694.8%+1.4
Q4 FY2025Dec 31, 202595.5%+6.9
Q3 FY2025Sep 30, 202595.2%+57.6
Q2 FY2025Jun 30, 202552.2%+32.5
Q1 FY2025Mar 31, 202593.4%−1.5
Q4 FY2024Dec 31, 202488.7%−1.8
Q3 FY2024Sep 30, 202437.7%−57.4
Q2 FY2024Jun 30, 202419.7%−72.3
Q1 FY2024Mar 31, 202494.9%−1.2
Q4 FY2023Dec 31, 202390.5%−8.4
Q3 FY2023Sep 30, 202395.0%−0.1
Q2 FY2023Jun 30, 202392.0%−4.1
Q1 FY2023Mar 31, 202396.1%−3.7
Q4 FY2022Dec 31, 202298.9%+1.2
Q3 FY2022Sep 30, 202295.1%−4.9
Q2 FY2022Jun 30, 202296.1%+4.4
Q1 FY2022Mar 31, 202299.8%+653.9
Q4 FY2021Dec 31, 202197.7%+6.4
Q3 FY2021Sep 30, 2021100.0%–
Q2 FY2021Jun 30, 202191.7%–
Q4 FY2019Dec 31, 2019-554.1%–
Q3 FY2019Sep 30, 201991.3%–

More Zevra Therapeutics figures

See a number that looks wrong?